NDA 017744 · Legacy
Motofen Half-Strength
Atropine Sulfate, Difenoxin Hydrochloride · Oral
NovelLast checked: Nov 20, 2026Latest source record: Mar 28, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1978
Jul 14, 1978
Approved uses
1
Original approval plus efficacy supplements
Registered trials
414
74 Phase 3, 30 recruiting
FAERS reports
26
15 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 23, 2026.
INDICATIONS AND USAGE MOTOFEN ® is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 14, 1978 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination
2 products under this application
- MOTOFEN HALF-STRENGTH · ATROPINE SULFATE 0.025MG; DIFENOXIN HYDROCHLORIDE 0.5MG · TABLET, ORAL · Discontinued
- MOTOFEN · ATROPINE SULFATE 0.025MG; DIFENOXIN HYDROCHLORIDE 1MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Atropine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00400153 · 1,480 participants · Start Nov 2006 · Primary completion Apr 2008
Drug: Atrovent Respimat (20 mcg); COMBIVENT MDI (36/206 mcg) and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Jasper, Alabama; Mobile, Alabama · 180 sites in all
- Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01422304 · 1,198 participants · Start Oct 12, 2011 · Primary completion Sep 26, 2012
Drug: Sugammadex; neostigmine and glycopyrrolate or atropine and 2 more · For: Neuromuscular Blockade; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee and 2 more
- Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02177253 · 1,118 participants · Start Oct 2002 · Primary completion Mar 2004
Drug: Ipratropium bromide / Salbutamol; Placebo Inhalation solution and 3 more · For: Pulmonary Disease, Chronic Obstructive
- A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible BronchoscopyPivotal-lookingStatus unknown
Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
NCT06376942 · 1,050 participants (planned) · Start Apr 24, 2024 · Primary completion Apr 25, 2025
Drug: Glycopyrronium; Ipratropium · For: Subjects Undergoing Flexible Bronchoscopy
Sites: Chandigarh, India
- Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) OutcomePivotal-lookingCompleted
Petter Andreas SteenAcademic, hospital or other
NCT00121524 · 904 participants · Start Jan 2003 · Primary completion May 2008
Drug: Epinephrine; Atropine and 1 more · For: Cardiac Arrest
Sites: Oslo, Norway
- The Safety and Efficacy of SYD-101 in Children With MyopiaPivotal-lookingCompleted
Sydnexis, Inc.Industry
NCT03918915 · 852 participants · Start Apr 24, 2019 · Primary completion May 2, 2024
Drug: SYD-101 0.01%; SYD-101 0.03% and 1 more · For: Nearsightedness; Near Sightedness; Near-sightedness
Sites: Irwindale, California; Pasadena, California; San Diego, California · 47 sites in all
- A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye DropsPivotal-lookingActive, not recruiting
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Industry
NCT06209320 · 777 participants (planned) · Start Mar 15, 2022 · Primary completion Mar 21, 2025
Drug: Lower dose atropine sulfate eye drops; Low dose atropine sulfate eye drops and 1 more · For: Myopia
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting4
- diarrhoea3
- drug ineffective3
- nausea3
- pain3
- product dose omission issue3
- bone disorder2
- fall2
- irritable bowel syndrome2
- product availability issue2
- abdominal distension1
- abdominal pain1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 5 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2025 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Motofen (Difenoxin HCl/Atropine Sulfate)
2024 spending
$574K
Beneficiaries
139
672 claims
Per beneficiary
$4,128
$6.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $857,454 |
| 2021 | $786,722 |
| 2022 | $707,800 |
| 2023 | $616,328 |
| 2024 | $573,746 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.
Yam JC, Jiang Y, Tang SM, et al. · Ophthalmology 2019 · Clinical Trial, Phase I, Randomized Controlled Trial
- Effectiveness of atropine in managing sialorrhea: A systematic review and meta-analysis.
Yellepeddi VK, Race JA, McFarland MM, et al. · Int J Clin Pharmacol Ther 2024 · Systematic Review, Meta-Analysis
- Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial.
Yam JC, Zhang XJ, Zhang Y, et al. · JAMA 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Myopia control strategies: A systematic review and meta-meta-analysis.
Zaabaar E, Asiamah R, Kyei S, et al. · Ophthalmic Physiol Opt 2025 · Systematic Review, Meta-Analysis
- Myopia prevention and control in children: a systematic review and network meta-analysis.
Zhang G, Jiang J, Qu C · Eye (Lond) 2023 · Systematic Review, Network Meta-Analysis
- Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials.
Fornaro M, Caiazza C, Solini N, et al. · Mol Psychiatry 2023 · Systematic Review, Network Meta-Analysis
Sponsor: Legacy · Also marketed as Motofen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.